Biotech Values

[flatlander_60048]

FTY 720

Assuming FDA follows the recommendation within the expedited review period (next 2 months or so), which existing pharma stand to lose the most in the MS market:

A) Biogen
B) Teva
C) Elan
D) others

Even if the approval comes in the next couple of months, NVS owners should not gloat since there are already other oral MS drugs in late stage testing.

FL